Yingfang Feng

机构：Jiangsu University, Xuzhou Medical College, Tianjin Medical University Cancer Institute and Hospital, Xuzhou Cancer Hospital · ORCID：0000-0002-5034-8879

发表论文 17 篇 · 总被引 257 次 · h-index 4

代表论文

• anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells (2020 · Cell Death and Disease · 被引 188)
• CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma (2024 · Cancer Research · 被引 29)
• Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers (2024 · European Journal of Cancer · 被引 18)
• Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K / AKT signaling can be reversed by anlotinib (2023 · Cancer Medicine · 被引 16)
• Single-cell and bulk transcriptomics reveal a CD8+ T-cell gene signature predicting prognosis in diffuse large B-cell lymphoma (2025 · Frontiers in Immunology · 被引 2)
• An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma (2024 · Expert Opinion on Biological Therapy · 被引 2)